New Peptide and Antibody Approaches Target Sodium Channels to Silence Neuropathic Pain

Key points

• Mimetic Medicines' peptide disrupts the interaction between Nav1.8 and the scaffolding protein Ank3, reducing channel density in the cell membrane of mice.
• University of Toyama and Shionogi researchers developed humanized antibodies targeting Nav1.7 that provided pain relief in rats for up to 96 hours, outlasting the effects of pregabalin.
• Both studies emphasize the potential to selectively silence abnormal pain signals while preserving normal nociception, a key challenge in current pain management.
• Mimetic’s approach focuses on channel trafficking via a 'bait molecule' mechanism, whereas the antibody approach directly blocks channel activity with high selectivity.
• Current standard treatments include gabapentinoids and SNRIs, while Vertex Pharmaceuticals’ Nav1.8 inhibitor Journavx is approved for acute but not neuropathic pain.

Background

Recent research has explored various non-opioid avenues for pain relief, including the repurposing of cancer drugs like BRAF inhibitors and the use of psychedelics such as psilocybin for chemotherapy-induced neuropathy. These new sodium channel studies add to a growing body of evidence suggesting that modulating ion channel dynamics or expression can effectively manage chronic pain without the side effects associated with traditional analgesics.

How outlets are covering it

Fierce Biotech highlights Mimetic’s peptide as a novel method to alter channel trafficking, noting that the technology is adaptable to other targets. SciTechDaily emphasizes the antibody approach’s ability to provide sustained relief while preserving motor function and normal pain sensation, a critical safety advantage over pregabalin. Inside Precision Medicine frames the peptide study as a method to quiet chronic signals while maintaining protective pain, aligning with the broader goal of selective analgesia. While Fierce focuses on the mechanism of channel reduction, SciTechDaily details the clinical potential of the antibody, noting that one candidate is already in trials. The outlets differ in their emphasis: Fierce discusses the foundational science of channel dynamics, while SciTechDaily focuses on the practical efficacy and safety profile of the antibody in animal models.

Why it matters

Neuropathic pain remains difficult to treat with existing medications, which often have significant side effects or limited efficacy. These studies suggest that targeting specific sodium channels like Nav1.7 and Nav1.8 could provide a more precise way to block abnormal pain signals without dulling the body’s natural warning systems. If successful in human trials, these approaches could offer long-lasting relief for patients suffering from chronic nerve pain, potentially reducing the reliance on opioids and other drugs with severe adverse effects.

What to watch

Mimetic Medicines is evaluating multiple SLiP candidates derived from the prototype peptide, aiming to expand the technology to other channelopathies. The antibody S-151128 is already in clinical trials to test its safety and efficacy in humans. Further research is needed to determine how well these treatments translate from animal models to human patients and to assess their long-term safety and effectiveness across different types of neuropathic pain.